AstraZeneca has announced filing a legal challenge to certain aspects of the U.S. Inflation Reduction Act (IRA), arguing that there may be unintended but harmful consequences for people living with rare diseases such as neuromyelitis optica spectrum disorder (NMOSD). It joins a number of other pharmaceutical companies…
Orphan drug status
Recent Posts
- Navigating NMOSD at the intersection of culture and family
- Review shows approved treatment sharply cuts relapse risk in NMOSD
- Choosing courage and connection after the trauma of NMOSD
- NMOSD patients report lower sleep quality, study shows
- The bra line battle is a wardrobe crisis for women with NMOSD